Q Biomed inc   (QBIO)
Other Ticker:  
Price: $0.0002 $0.00 100.000%
Day's High: $0.0002 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf: -71.43 %
Volume (M): 1 52 Wk High: $ 0.02
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 109
 Employees 8
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Q Biomed Inc

We are a biotechnology acceleration and development company focused on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. Currently, we have a portfolio of four therapeutic products, including an FDA approved product, Strontium 89, a radiopharmaceutical for metastatic cancer bone pain, and three development stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma. We aim to maximize risk-adjusted returns by focusing on multiple assets throughout the discovery and development cycle. We expect to benefit from early positioning in illiquid and/or less well known privately-held assets, thereby enabling us to capitalize on valuation growth as these assets move forward in their development.

Our goal is to become a leading biotechnology acceleration and development company with a diversified portfolio of therapeutic products commercially available and in development. To achieve this goal, we are executing on the following strategy:

Strategically collaborate or in- and out-license select programs.
We seek to collaborate or in- and out-license certain potentially therapeutic candidate products to biotechnology or pharmaceutical companies for preclinical and clinical development and commercialization.

Highly leverage external talent and resources.
We plan to maintain and further build our team which is skilled in evaluating technologies for development and product development towards commercialization. By partnering with industry specific experts, we are able to identify undervalued assets that we can fund and assist in enhancing inherent value. We plan to continue to rely on the extensive experience of our management team to execute on our objectives.

Evaluate commercialization and monetization strategies on a product-by-product basis in order to maximize the value of our product candidates or future potential products.

As we move our drug candidates through development toward regulatory approval, we will evaluate several options for each drug candidate’s commercialization or monetization strategy. These options include building our own internal sales force; entering into a joint marketing partnership with another pharmaceutical or biotechnology company, whereby we jointly sell and market the product; and out-licensing any product that we develop by ourselves or jointly with another party, whereby another pharmaceutical or biotechnology company sells and markets such product and pays us a royalty on sales. Our decision will be made separately for each product and will be based on a number of factors including capital necessary to execute on each option, size of the market to be addressed and terms of potential offers from other pharmaceutical and biotechnology companies. It is too early for us to know which of these options we will pursue for our drug candidates, assuming their successful development.

Acquire commercially or near-commercially ready products and build out the current market for such.
In addition to acquiring pre-clinical products, in assembling a diversified portfolio of healthcare assets, we plan on acquiring assets that are either FDA approved or are reasonably expected to be FDA approved within 12 months of our acquiring them. We anticipate hiring a contract sales organization to assume the bulk of the sales and distribution efforts related to any such product.

   Company Address: c/o Ortoli Rosenstadt LLP New York 10017 NY
   Company Phone Number: 588-0022   Stock Exchange / Ticker: QBIO
   QBIO is expected to report next financial results on May 25, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Q Biomed Inc

Q Biomed Inc Makes Strides in 2023: Narrowed Losses Mirror Last Year's Performance

Q Biomed Inc, a renowned pharmaceutical company, recently released its financial results for the fiscal period ending February 28, 2023. The company reported a significant reduction in losses compared to the previous year, showcasing a promising path towards recovery. Investors and stakeholders have taken notice of Q Biomed Inc's ability to gradually improve its financial standing, indicating positive potential for the future.
In the fiscal period ending February 28, 2023, Q Biomed Inc recorded a loss of $-0.02 per share, a notable increase from the loss of $-0.08 per share reported during the same period the previous year. Additionally, the company's earnings per share (EPS) declined from $0.02 per share in the previous reporting period. These figures illustrate a significant improvement in the company's performance and its ability to efficiently manage its expenses.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com